Sun Pharma Advanced Research Company532872Pharmaceuticals
Analyst Kunal expects double-digit constant currency growth in Sun Pharma's specialty business this quarter, with updates awaited on the organon acquisition closing expected in Q1 calendar 2027
By ScoutQuest · · 1 min read
Heard on business television between 12:18:37 - 12:21:37 IST.
- Specialty business expected to post double digit year-on-year growth on constant currency basis
- Existing products like Ilumya, Cequa and Winlevi continue to do well
- Watching for management commentary on new launches Unloxcyt and Leqselvi
- Organon acquisition unlikely to be commented on this quarter as deal has not yet closed, guided to close in Q1 calendar year 2027
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Sun Pharma Advanced Research Company
Board meeting on November 2 to approve unaudited results for quarter and half year ended September 30, 2026
22 Oct 2026
CESTAT upholds order in company's favour, confirms entitlement to refund of CENVAT credit of Rs. 2751 Lakhs
4 Oct 2026
Sun Pharma signed a global exclusive licensing deal with LIB Therapeutics to commercialize a cholesterol-lowering drug outside the US and China, sparking bullish brokerage views
29 Sep 2026
Source: Live TV News Channel · 16 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.